WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Understanding The Interplay Between Severe Combined Immunodeficiency (SCID) And Pulmonary Fibrosis: Mechanisms, Implications, And Therapeutic Considerations

Amandeep[1], Rajnath Singh Kushwaha[1], Ms. Zeenat Parveen[2], Sonia[1] , Aniket Sharma[1], Akhil[1]

[1-]CT Institute of Pharmaceutical Sciences, Shahpur, Jalandhar City, 144020, India

[2-]*CT College of Pharmacy, Shahpur, Jalandhar City, 144020, India*

ABSTRACT :

Severe Combined Immunodeficiency (SCID) and Pulmonary Fibrosis are distinct yet interconnected medical conditions that pose significant challenges to affected individuals. SCID, characterized by profound immune system dysfunction, particularly affects T cells due to genetic mutations. This genetic impairment predisposes individuals to recurrent and severe infections from early infancy, necessitating prompt intervention with therapies like hematopoietic stem cell transplantation (HSCT) or gene therapy. Despite successful immune reconstitution, SCID patients may develop pulmonary complications, including fibrosis, which can profoundly impact long-term health outcomes. Pulmonary Fibrosis, on the other hand, involves the progressive formation of scar tissue in the lungs, leading to impaired lung function and respiratory symptoms such as dyspnea and persistent cough. Causes range from environmental exposures to autoimmune disorders, and management includes anti-fibrotic medications, oxygen therapy, and potentially lung transplantation. The association between SCID and Pulmonary Fibrosis underscores the complex

Keywords: Severe Combined Immunodeficiency (SCID), Pulmonary Fibrosis, Immune system dysfunction, T cell deficiency, Hematopoietic stem cell transplantation (HSCT), Gene therapy, Recurrent infections, Lung complications, Scar tissue formation, Respiratory symptoms, Anti-fibrotic medications, Lung transplantation, Immune dysregulation, Chronic lung pathology

1. INTRODUCTION :

1.1 Severe Combined Immunodeficiency (SCID)

A severe immune system impairment is the hallmark of the rare genetic disorder known as severe combined immunodeficiency (SCID). The disorder is usually present from birth and is caused by mutations in genes that control the growth and operation of immune cells, especially T cells and occasionally B cells. These genetic defects prevent the immune system from effectively fighting off infections caused by bacteria, viruses, fungi, and other pathogens [35].

1. **Genetic Basis:** SCID can be inherited in an autosomal recessive manner, where both parents carry a defective gene that is passed on to the child. Mutations in genes such as IL2RG (encoding the common gamma chain), ADA (adenosine deaminase), and others can lead to different forms of SCID [16].
2. **Immune System Deficiency:** The hallmark of SCID is the absence or severe impairment of T lymphocytes (T cells), which play a crucial role in coordinating immune responses. This deficiency leaves individuals highly susceptible to infections that would typically be controlled or eliminated by a healthy immune system [5].
3. **Clinical Presentation:** Infants with SCID often present with recurrent, severe infections early in life. These infections can affect various organs and systems, including the respiratory tract, gastrointestinal tract, and skin. The infections can be life-threatening if not promptly treated [29]
4. **Treatment Options:** Historically, SCID had a very poor prognosis without treatment, often leading to death in infancy or early childhood due to overwhelming infections. But thanks to developments in medicine, therapies like gene therapy and hematopoietic stem cell transplantation (HSCT) may now be able to cure patients. These approaches aim to restore the function of the immune system by providing healthy stem cells or correcting the genetic defect responsible for SCID [1][24].
5. **Impact on Quality of Life:** Even with successful treatment, individuals with SCID may face ongoing challenges related to their immune function, requiring careful management of infections and potentially lifelong medical follow-up [12].

1.2 Pulmonary Fibrosis

A progressive lung disease called pulmonary fibrosis is indicated by the development of scar tissue, or fibrosis, in the lungs. This scar tissue replaces healthy lung tissue, impairing the ability of the lungs to function properly. Over time, the lungs become stiff and lose their elasticity, which makes it difficult for oxygen to pass through the walls of the air sacs into the bloodstream [28]

1. **Pathophysiology:** The exact cause of pulmonary fibrosis is often unknown (idiopathic), but it can result from various factors including environmental exposures (such as asbestos or silica dust), certain medications, radiation therapy, autoimmune conditions, and genetic factors. In some cases, it can be associated with other diseases such as rheumatoid arthritis or scleroderma [23]
2. **Symptoms:** Patients with pulmonary fibrosis may experience progressive dyspnea (shortness of breath), particularly during exertion. As the disease advances, individuals may also develop a persistent dry cough, fatigue, unexplained weight loss, and discomfort in the chest [19]
3. **Diagnostic Tools:** Diagnosis typically involves a combination of clinical evaluation, pulmonary function tests (PFTs) to assess lung function, imaging studies such as chest X-rays and high-resolution CT scans, and sometimes lung biopsy to confirm the presence of fibrosis [20].
4. **Prognosis and Management:** The prognosis for pulmonary fibrosis varies widely depending on factors such as the underlying cause, the extent of fibrosis, and the individual's overall health. The goals of treatment are to lessen symptoms, enhance quality of life, and slow the progression of the disease. Medication (such as immunosuppressants and corticosteroids), oxygen therapy, pulmonary rehabilitation, and in certain situations, lung transplantation are examples of therapeutic options [34].
5. **Challenges:** Living with pulmonary fibrosis can pose significant challenges due to the progressive nature of the disease and its impact on daily activities and overall well-being. Patients often require ongoing medical care and support from healthcare providers and may benefit from involvement in support groups or pulmonary rehabilitation programs [36].

2. OVERVIEW OF SEVERE COMBINED IMMUNODEFICIENCY (SCID)

Causes of SCID

Severe Combined Immunodeficiency (SCID) is primarily caused by genetic mutations that disrupt the development or function of immune cells, particularly T cells. T cells are crucial components of the adaptive immune system, responsible for recognizing and responding to specific pathogens.

Genetic Basis:

1. **X-linked SCID:** The most common form of SCID is X-linked SCID (XSCID), which accounts for about 50% of cases. It is brought on by mutations in the X chromosome-based IL2RG gene. This gene encodes the common gamma chain (γc) protein, which is a component of receptors for several interleukins (IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21). These interleukins are essential for the development and function of T cells and natural killer (NK) cells [5].
2. **Autosomal Recessive SCID:** Other forms of SCID are inherited in an autosomal recessive pattern, meaning both parents must carry a copy of the defective gene. Examples include mutations in genes such as ADA (adenosine deaminase), IL7R (IL-7 receptor), JAK3 (Janus kinase 3), RAG1 (recombination activating gene 1), and RAG2 (recombination activating gene 2). These mutations impair various aspects of T cell development or signaling, leading to immune deficiency [6].
3. **Other Rare Causes:** There are also rare forms of SCID caused by mutations in other genes involved in immune cell development or function, such as DCLRE1C (encoding Artemis protein) and AK2 (adenylate kinase 2) [37]

Symptoms of SCID

The symptoms of SCID typically manifest early in life, often within the first few months after birth, when maternal antibodies acquired during pregnancy begin to decline. The severity and types of infections can vary depending on the specific genetic defect and the degree of immune system impairment [9][7].

Common Symptoms Include:

1. **Recurrent Infections:** Infants with SCID are highly susceptible to severe, recurrent infections caused by bacteria, viruses, fungi, and protozoa. These infections can affect multiple organs and systems, including the respiratory tract (pneumonias), gastrointestinal tract (chronic diarrhoea), and skin (severe rashes).
2. **Failure to Thrive:** Infants may fail to gain weight and grow normally (failure to thrive), despite adequate caloric intake. This is often due to the energy demands imposed by ongoing infections and the metabolic stress of immune system dysfunction.
3. **Susceptibility to Opportunistic Infections:** Patients with sickle cell disease (SCID) are more susceptible to opportunistic infections, which are caused by pathogens that normally do not cause illness in healthy people. Examples include Pneumocystis jirovecii (causing pneumonia), cytomegalovirus (CMV), and candida species.

Diagnosis of SCID

Early diagnosis of SCID is crucial for timely intervention and treatment, as untreated SCID can be fatal due to overwhelming infections.

Diagnostic Approaches:

1. **Newborn Screening:** In some regions, SCID is included in newborn screening programs, which involve testing for the presence of T cell receptor excision circles (TRECs) or other markers of T cell development in dried blood spots. Low or absent TRECs suggest a potential immune deficiency.

2. **Clinical Evaluation:** Infants suspected of having SCID undergo a thorough clinical evaluation, focusing on medical history (recurrent infections), family history (consanguinity or previous affected siblings), and physical examination (signs of lymphopenia or growth failure).
3. **Genetic Testing:** Confirmation of SCID often requires genetic testing to identify specific mutations in genes associated with immune system function. This may involve sequencing genes known to be involved in SCID or using targeted genetic panels.
4. **Immunological Studies:** Immunological assays are performed to assess immune cell populations and their function. This includes measuring lymphocyte subsets (T cells, B cells, NK cells), evaluating responses to mitogens and antigens, and assessing immunoglobulin levels.
5. **Bone Marrow Biopsy:** In some cases, a bone marrow biopsy may be performed to evaluate the ability of hematopoietic stem cells to generate mature immune cells [32][17].

3. TREATMENT AND MANAGEMENT OF SCID

Severe Combined Immunodeficiency (SCID) requires prompt and comprehensive treatment to address the underlying immune deficiency and manage associated complications. Current approaches include a combination of curative treatments and supportive care measures.

Current Approaches

1. Stem Cell Transplantation (SCT):

- **Overview:** Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for SCID, particularly effective for certain genetic types such as ADA-SCID and IL2RG (XSCID).
- **Procedure:** HSCT involves the infusion of healthy donor stem cells (typically from bone marrow, peripheral blood, or umbilical cord blood) into the patient. These stem cells can repopulate the bone marrow and generate functional immune cells, correcting the immune deficiency.
- **Successes:** HSCT has shown high success rates in restoring immune function in SCID patients, especially when performed early in life before significant infections occur.
- **Challenges:** Challenges include finding a suitable donor match, managing potential complications such as graft-versus-host disease (GVHD) where donor immune cells attack the recipient's tissues, and ensuring long-term immune reconstitution [5][1].

2. Gene Therapy:

- **Overview:** By introducing a functional copy of the faulty gene into the patient's own cells, gene therapy seeks to correct the genetic defect causing sickle cell disease (SCID).
- **Techniques:** This can be achieved using viral vectors to deliver the corrected gene into hematopoietic stem cells ex vivo (outside the body) or directly in vivo (inside the body).
- **Successes:** Gene therapy has shown promising results, particularly in ADA-SCID and XSCID. Patients treated with gene therapy have demonstrated significant immune reconstitution and reduced dependence on lifelong immunoglobulin replacement therapy.
- **Challenges:** Challenges include the risk of insertional mutagenesis (where the introduced gene disrupts normal cell function), immune responses against viral vectors, and ensuring sustained and adequate gene expression over time [15][10].

3. Enzyme Replacement Therapy [4][31]

- **For ADA-SCID:** ADA deficiency can be managed with enzyme replacement therapy (ERT), where recombinant ADA enzyme is administered to help metabolize toxic metabolites that accumulate in immune cells due to ADA deficiency.
- **Supportive:** ERT can provide temporary relief from symptoms but is not curative like HSCT or gene therapy [4][31].

Supportive Care

1. Infection Prevention and Management:

- **Prophylactic Antibiotics:** SCID patients often receive prophylactic antibiotics to prevent bacterial infections. Antibiotics may be prescribed continuously or during periods of increased infection risk.
- **Antiviral Prophylaxis:** Depending on the specific viral risks, antiviral medications may be used to prevent infections with viruses like cytomegalovirus (CMV) or herpes simplex virus (HSV).
- **Fungal Prophylaxis:** Antifungal medications may be considered to prevent fungal infections, which can be particularly challenging in SCID patients [13].

2. Immunoglobulin Replacement Therapy:

- **Purpose:** Many SCID patients require regular infusions of immunoglobulins (antibodies) to provide passive immunity against pathogens, supplementing their impaired immune response.
- **Administration:** Immunoglobulins are typically administered intravenously (IVIG) or subcutaneously (SCIG) on a regular schedule to maintain protective antibody levels [1].

3. Environmental Modifications:

- **Avoidance of Live Vaccines:** SCID patients should avoid live vaccines due to the risk of causing serious infections.

- **Isolation Precautions:** Infections can be particularly dangerous for SCID patients, so minimizing exposure to sick individuals and maintaining strict hygiene practices are crucial.

IMPACT OF SCID ON PULMONARY FIBROSIS

Severe Combined Immunodeficiency (SCID), particularly types involving T-cell dysfunction, can indeed have significant implications for the development of pulmonary fibrosis. Understanding the association, mechanisms, and supporting research helps elucidate the relationship between these two conditions.

Association Between SCID and Pulmonary Fibrosis

1. Types of SCID and Lung Complications:

- SCID encompasses various genetic disorders that impair immune system function, particularly T-cell immunity. Types such as IL2RG (XSCID) and ADA deficiency (ADA-SCID) are notable for their severe T-cell deficiency.
- Individuals with SCID, especially those with prolonged and severe immune compromise, are at increased risk of developing pulmonary complications, including pulmonary fibrosis [32].

2. Clinical Observations:

- Case studies and clinical reports have documented instances where SCID patients, particularly those with delayed diagnosis or inadequate immune reconstitution despite treatment, develop chronic lung disease characterized by fibrosis.
- The exact prevalence and mechanisms underlying this association are still being studied, but immune dysregulation plays a crucial role in predisposing these patients to lung pathology [5].

Mechanisms of Pulmonary Fibrosis in SCID Patients

1. Immune Dysregulation:

- **Chronic Inflammation:** Persistent infections and inadequate immune responses in SCID patients can lead to chronic inflammation within the lungs. This sustained inflammatory state can contribute to tissue damage and fibrosis.
- **Altered Immune Responses:** Dysfunctional T-cell responses or imbalances in cytokine production (e.g., excess pro-inflammatory cytokines) can exacerbate lung tissue injury and promote fibrotic changes.
- **Secondary Infections:** Recurrent respiratory infections, often caused by opportunistic pathogens, can directly damage lung tissue and trigger fibrotic responses as part of the healing process [25].

2. Impact of Treatment Modalities:

- While treatments such as stem cell transplantation and gene therapy aim to restore immune function in SCID patients, complications such as graft-versus-host disease (GVHD) or persistent immune deficiency can contribute to ongoing lung pathology.
- Immunosuppressive therapies used to manage GVHD, or autoimmune manifestations post-transplantation can further complicate pulmonary health by altering immune responses and increasing susceptibility to infections [2].

Case Studies and Research Findings

1. Research Insights:

- Studies have highlighted cases of SCID patients developing pulmonary fibrosis as a long-term complication, particularly in the context of chronic infections and unresolved immune dysregulation.
- Genetic studies and animal models have provided insights into specific pathways (e.g., cytokine signaling, fibroblast activation) involved in fibrosis development in the setting of immune deficiency [14].

2. Clinical Examples:

- A retrospective study involving SCID patients treated with hematopoietic stem cell transplantation noted a subset developing pulmonary complications, including interstitial lung disease and fibrosis, despite successful immune reconstitution in other aspects.
- Longitudinal monitoring of SCID patients post-treatment has underscored the need for vigilance in identifying and managing respiratory symptoms early to mitigate progression to fibrotic lung disease [5].

OVERVIEW OF PULMONARY FIBROSIS

A progressive lung disease called pulmonary fibrosis is defined by the development of scar tissue, or fibrosis, in the lungs that eventually supplants healthy lung tissue and reduces lung function. Understanding its causes, symptoms, diagnosis, and treatment is essential for managing this chronic condition effectively.

Causes of Pulmonary Fibrosis

1. Idiopathic Pulmonary Fibrosis (IPF):

- Idiopathic refers to the majority of cases (roughly 50%), in which the cause is not known. It is thought to be the outcome of a confluence of environmental and genetic predispositions [18].

2. Environmental and Occupational Exposures:

- **Exposure to Dusts and Fibers:** Inhalation of asbestos fibers, silica dust, coal dust, and other occupational exposures can lead to lung scarring over time.
- **Medications and Radiation:** Certain medications (e.g., chemotherapy drugs like methotrexate, heart medications like amiodarone) and therapeutic radiation to the chest can cause lung damage and fibrosis [13].

3. Autoimmune Disorders:

- **Connective Tissue Diseases:** Conditions such as rheumatoid arthritis, systemic sclerosis (scleroderma), and lupus can be associated with pulmonary fibrosis due to immune system dysregulation and inflammation affecting lung tissue [8].

4. Other Causes:

- **Infections:** Chronic infections such as tuberculosis and pneumonia can sometimes lead to scarring of lung tissue.
- **Genetic Factors:** Rare genetic mutations can predispose individuals to familial forms of pulmonary fibrosis.
- **Unknown Factors:** In some cases, no specific cause can be identified despite thorough evaluation [26].

Symptoms of Pulmonary Fibrosis

1. Respiratory Symptoms:

- Shortness of Breath (Dyspnea): Gradually worsening over time, especially during physical exertion.
- Persistent Dry Cough: Often unresponsive to typical cough medications.
- Fatigue: Due to reduced oxygenation of the blood and increased effort required for breathing [21].

2. Other Symptoms:

- Clubbing of Fingers and Toes: Enlargement and rounding of the tips of the fingers and toes due to chronic lack of oxygen in the blood.
- Weight Loss: Unintentional weight loss can occur due to the increased energy expenditure associated with breathing difficulties [33].

Diagnosis and Treatment of Pulmonary Fibrosis

1. Diagnostic Approaches:

- **Imaging Studies:** High-resolution computed tomography (HRCT) scan of the chest is the primary imaging tool to visualize lung abnormalities characteristic of fibrosis (honeycombing, reticular opacities).
- **Pulmonary Function Tests (PFTs):** Spirometry and diffusion capacity tests measure lung function and assess the severity of impairment.
- **Lung Biopsy:** In some cases, a surgical lung biopsy may be necessary to confirm the diagnosis and rule out other conditions [27].

2. Treatment Strategies:

Medications:

- **Anti-fibrotic Therapy:** Drugs like pirfenidone and nintedanib can slow the progression of pulmonary fibrosis by reducing lung scarring and inflammation.
- **Immunosuppressants:** In cases associated with autoimmune disorders, medications that suppress the immune system may be used to reduce lung inflammation.
- **Oxygen Therapy:** Supplemental oxygen is prescribed to maintain adequate oxygen levels in the blood and relieve symptoms of hypoxia (low oxygen).
- **Pulmonary Rehabilitation:** Programs including exercise training, breathing techniques, and education can help improve quality of life and functional capacity.
- **Lung Transplantation:** For severe cases where other treatments fail, lung transplantation may be considered to improve survival and quality of life [22].

3. Supportive Care:

- **Infection Prevention:** Vaccinations (excluding live vaccines), avoidance of sick individuals, and regular hand hygiene help prevent respiratory infections.
- **Nutritional Support:** Proper nutrition and hydration are important to maintain overall health and energy levels.
- **Emotional Support:** Living with pulmonary fibrosis can be challenging, so support groups and counseling may be beneficial for patients and caregivers [30].

CONCLUSION:

The intricate connection between Severe Combined Immunodeficiency (SCID) and Pulmonary Fibrosis underscores the complex interplay of immune system dysfunction and its profound impact on lung health. SCID, characterized by severe impairment in immune function, often leads to various complications, including pulmonary fibrosis. This condition manifests through mechanisms such as chronic inflammation and altered immune responses, which contribute to the progressive scarring of lung tissue seen in pulmonary fibrosis. Early detection of these pulmonary complications is crucial for effective management. Recent advances in therapeutic approaches like Hematopoietic Stem Cell Transplantation (HSCT) and gene therapy hold promise in restoring immune function in SCID patients. However, there is a pressing need for continued vigilance to minimize long-term pulmonary complications associated with these treatments. Future research efforts are essential to deepen our understanding of immune system dynamics, genetic predispositions influencing disease progression, and the development of innovative treatment strategies. These endeavors are pivotal in improving both the prognosis and quality of life for individuals grappling with these complex illnesses, ensuring that they receive timely and effective care tailored to their specific medical needs.

REFERENCES :

1. 1. Al-Herz W, Bousfiha A, Casanova JL, et al. “Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. J Clin Immunol. 2015 Jul;35(8):696-726.
2. Antoine C, Müller S, Cant A, et al. “Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99”. Lancet. 2003;361(9357):553-560.
3. Baumgartner KB et al. Occupational and Environmental Risk Factors for Idiopathic Pulmonary Fibrosis: A Multicenter Case-Control Study. Collaborating Centers. 2000; 162(4):1172-1177.
4. Booth C, Gaspar HB. “Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID)”. Biologics. 2009 Sep 2;3:349-58.
5. Buckley RH “Molecular Defects in Human Severe Combined Immunodeficiency and Approaches to Immune Reconstitution” Annual Reviews. 2004; 22:625-655 https://doi.org/10.1146/annurev.immunol.22.012703.104614
6. Cavazzana-Calvo M, Fischer A. “Gene therapy for severe combined immunodeficiency: are we there yet?” J Clin Invest. 2007 Oct;117(10):1456-65.
7. Chan AY, Leung DY. “How to interpret and pursue an abnormal complete blood cell count in adults”. Mayo Clin Proc. 2005 Mar;80(3):348-64.
8. Fischer A et al. The Diffuse Parenchymal Lung Diseases: Idiopathic Interstitial Pneumonias and Pulmonary Langerhans Cell Histiocytosis. European Respiratory Review. 2015; 24:69-77.
9. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. “Gene therapy of primary T cell immunodeficiencies”. Gene. 2013 Jun 15;525(2):170-3.
10. Gaspar HB, Aiuti A, Porta F, et al. “How I treat ADA deficiency”. Blood. 2009 Dec 24;114(17):3524-32. doi:10.1182/blood-2009-06-189209.
11. Gaspar HB, Qasim W, Davies EG. “How I treat severe combined immunodeficiency”. *Blood.* 2013 Jul 18;122(23):3749-58. https://doi.org/10.1182/blood-2013-02-380105
12. Griffith LM, Cowan MJ, Kohn DB, Notarangelo LD, Puck JM, Pai SY. “Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs”. *J Allergy Clin Immunol.* 2008 Sep;122(3):1087-96 https://doi.org/10.1016/j.jaci.2008.09.045
13. Griffith LM, Cowan MJ, Notarangelo LD, et al. ‘Primary Immune Deficiency Treatment Consortium (PIDTC) update”. J Allergy Clin Immunol. 2016 Dec;138(6):1691-1705.
14. Griffith LM, Cowan MJ, Notarangelo LD, et al. “Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management”. J Allergy Clin Immunol. 2009;124(6):1152-1160.
15. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. “A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency”. N Engl J Med. 2003 Jan 16;348(3):255-6. doi:10.1056/NEJM200301163480314.
16. Hershfield MS¨Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy”. Seminars in Hematology, 01 Oct 1998, 35(4):291-298 PMID: 9801258
17. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, et al., “Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States”. JAMA. 2014 Aug 20;312(7):729-38.
18. Lederer DJ. Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2018; 378:1811-1823.
19. Ley B, Collard HR, King TE Jr. “Clinical course and prediction of survival in idiopathic pulmonary fibrosis”. *Am J Respir Crit Care Med. 2011* Mar 15;183(4):431-40 https://doi.org/10.1164/rccm.201006-0894CI
20. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. “A multidimensional index and staging system for idiopathic pulmonary fibrosis”. *Ann Intern Med.* 2012 Jun 5;156(10):684-91.
21. Maher TM et al. Idiopathic Pulmonary Fibrosis: Disease Mechanisms and Management. Frontiers in Medicine. 2019; 6:1-15.
22. Nathan SD et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. The Lancet. 2017; 377(9779):1760-1769.
23. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. “Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003”. *Am J Respir Crit Care Med.* 2007 Aug 15;176(4):277-84. https://doi.org/10.1164/rccm.200701-044OC

24. Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al' "Transplantation outcomes for severe combined immunodeficiency, 2000-2009". *N Engl J Med.* 2014 Jan 16;371(5):434-46. DOI: 10.1056/NEJMoa1401177
25. Puck JM. "Population-based newborn screening for severe combined immunodeficiency: steps toward implementation". J Allergy Clin Immunol. 2007;120(4):760-768. doi:10.1016/j.jaci.2007.08.050.
26. Raghu G et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine. 2018; 198(5)
27. Raghu G et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 2011; 183(6):788-824.
28. Richeldi L, Collard HR, Jones MG. "Idiopathic pulmonary fibrosis. *Lancet".* 2017 Mar 18;389(10082):1941-52. DOI:https://doi.org/10.1016/S0140-6736(17)30866-8
29. Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, Baker MW. "Statewide newborn screening for severe T-cell lymphopenia". *JAMA.* 2009 May 20;301(19):2044-51. doi:10.1001/jama.2009.1806.
30. Ryerson CJ et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis – a call for continued investigation. Respiratory Medicine. 2014; 108(3):441-449.
31. Sauer AV, Brigida I, Carriglio N, et al. "Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID". Blood. 2012 Apr 5;119(6):1428-39. doi:10.1182/blood-2011-08-376113.
32. Shearer WT, Dunn E, Notarangelo LD, et al. "Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience". J Allergy Clin Immunol. 2014;133(4):1092-1098. doi:10.1016/j.jaci.2013.09.044.
33. Swigris JJ et al. The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF. Respiratory Medicine. 2005; 99(9):1146-1152.
34. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS. "The SF-36 and SGRQ: validity and first look at minimum important differences in IPF". *Respir Med.* 2010 Nov;104(11):296-304. doi:10.1016/j.rmed.2009.09.006.
35. Tashar D & Dalal I. "The genetic basis of severe combined immunodeficiency and its variants" The Application of Clinical Genetics, 2012;67-80
36. Vancheri C, Failla M, Crimi N, Raghu G. "Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology". *Eur Respir J.* 2010 Mar;35(3):496-504. doi:10.1183/09031936.00077309.
37. Villa A, Notarangelo LD, Roifman CM. "Omenn syndrome: inflammation in leaky severe combined immunodeficiency". J Allergy Clin Immunol. 2008 Jun;121(6):1435-40.